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Abstract
We have previously shown that deregulated expression of the platelet-derived growth factor a-receptor (PDGFRA) can be associated with
neural tube defects (NTDs) in both men and mice. In the present study, we have investigated the transcription factors that control the up-
regulation of PDGFRA expression during differentiation of early embryonic human cells in culture. In Tera-2 embryonal carcinoma cells,
PDGFRA expression is strongly enhanced upon differentiation induced by retinoic acid and cAMP treatment. Here we show that the
corresponding increase in promoter activity is controlled by an ATTA-sequence-containing element located near the transcription initiation
site, which is bound by a transcriptional complex that includes PBX and PRX homeobox transcription factors. Mutation of the putative
binding sites for these transcription factors results in strong impairment of PDGFRA promoter activity in differentiated cells. Since functional
inactivation of Prx genes has been associated with NTDs in mice, these data support a model in which improper PDGFRA expression as a
result of mutations in or altered binding of its upstream regulators may be causally related to NTDs.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Neural tube defects (NTDs), including anencephaly
and spina bifida, form a major group of congenital
malformations with an average incidence of 1 per 1000
pregnancies in the western world. NTDs are multifactorial
traits with both genetic and environmental factors con-
tributing to their etiology. Several candidate genes for
NTDs have emerged from studies on mouse models, but
only few of them have actually been associated with
related diseases in humans. Mice with a targeted null
mutation in the gene encoding the platelet-derived growth
factor a-receptor (PDGFRA) and also Patch mutant mice,
which contain a natural deletion of the chromosomal
region that includes PDGFRA, both show severe spina
bifida combined with embryonic lethality in their homo-
zygous form [1,2]. We have recently shown that this gene
also plays a prominent role in the genesis of NTDs in
humans. Based on an analysis of naturally occurring
single nucleotide polymorphisms in the PDGFRA pro-
moter, five different promoter haplotypes could be dis-
criminated which strongly differed in their transcriptional
activity. Specific combinations of such haplotypes corre-
lated directly with a predisposition for NTDs in a group
of sporadic spina bifida patients [3]. Based on these
observations, we have postulated that aberrant transcrip-
tional regulation of PDGFRA may also play a central role
in the genesis of NTDs in humans.
The above hypothesis suggests that transcription fac-
tors that act as upstream regulators of PDGFRA expres-
sion may also be associated with NTDs. In line with this
concept, it has been shown that mice heterozygous for
the Patch deletion show spina bifida only in combination
with the undulated mutation in the Pax1 gene [4]. In a
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previous study, we have shown that Pax1 indeed acts as
an upstream transcriptional regulator of PDGFRA [5].
Moreover, we have shown that Pax1 carrying the undu-
lated mutation, as well as a mutant form of PAX1 found
in a patient with spina bifida [6], both show a gain of
function in their ability to stimulate PDGFRA transcrip-
tion [5]. Also, other transcription factors that have been
associated with NTDs in mouse models, including Pax3
[7], Gli2/Gli3 [8], HoxD4 [9,10] and Mfh1 [11] have
been associated directly with PDGFRA transcription or at
least coexpress with PDGFRA during development.
Expression of the PDGFRA and thus responsiveness of
cells to the various PDGF isoforms (PDGF-A, -B, -C and -D)
is strictly regulated during embryonic development.
Although present in all cells of the pre-implantation embryo
from the two-cell stage onwards [12], PDGFRA expression
becomes limited to mesodermal and certain neural crest-
derived structures after implantation [13–17]. Human
embryonal carcinoma (EC) cells, which represent the undif-
ferentiated stem cells of non-seminomatous testicular germ
cell tumors, are widely used as an in vitro model system for
studying differentiation-dependent regulation of gene ex-
pression during early human development [18]. In previous
studies, we have shown that the Tera-2 cell line in its
undifferentiated state (Tera-EC) expresses PDGFRA from
an internal promoter, giving rise to a set of alternative
transcripts that have been used as a specific marker for early
detection of testicular germ cell tumors [19,20]. Upon in
vitro treatment with retinoic acid (RA), differentiated cell
populations are obtained with neuronal and endodermal
characteristics, designated Tera-RA, which abundantly
express the 6.4 kb PDGFRA transcript that encodes the
full-length functional PDGFRA. Using the cloned 2 kb
promoter region of human PDGFRA that drives the forma-
tion of this 6.4 kb transcript, we have shown [21] in transient
transfection assays with a luciferase read-out, that PDGFRA
transcription is strongly up-regulated upon treatment of Tera-
EC cells with RA, particularly in combination with dibu-
tyryl-cAMP (Bt2cAMP) and theophylline, this in spite of the
fact that the promoter neither contains a consensus RA-
responsive element nor a consensus cAMP-responsive ele-
ment (CRE).
Based on the hypothesis that aberrant expression of
PDGFRA during development can be associated with
NTDs, we have investigated the transcription factors that
are involved in the up-regulation of PDGFRA promoter
activity during RA-induced differentiation of Tera-EC
cells. Here we show that an ATTA-sequence containing
element (parATTA) is essential for PDGFRA transcrip-
tional activity by binding a new complex of transcription
factors that includes the homeobox proteins PBX2 and
PRX2. Intriguingly, in mouse models, Prx genes have been
found to be associated directly with NTDs [22]. These data
underline the hypothesis that improper PDGFRA expres-
sion during development may be a major cause for the
genesis of NTDs.
2. Materials and methods
2.1. Reporter constructs
The construction of the truncated PDGFRA promoter-
luciferase (LUC) reporter gene vectors  2120/ + 118 LUC,
 441/ + 118 LUC,  275/ + 118 LUC,  197/ + 118 LUC,
 175/ + 118 LUC and  52/ + 118 LUC has been described
previously [21]. Mutant forms of these promoter-luciferase
constructs were generated using the Quick Change Site-
Directed Mutagenesis Kit (Stratagene).
2.2. Cell culture
The human embryonal carcinoma cell line Tera-2 clone
13 [23] was maintained in a-modification of minimal
essential medium lacking nucleosides and deoxynucleo-
sides, supplemented with 10% ES-approved fetal calf serum
(Gibco BRL). Undifferentiated cells were seeded 1 day prior
to transfection at high density (5.0 104 cells/cm2) in a
0.1% gelatin-coated tissue culture dish. Differentiation was
induced by the addition of 5 AM of RA, 12 h after the cells
were seeded at low density (5.0 103/cm2), and maintained
in this medium for 7 days before further use. Transfections
were carried out using the calcium-phosphate method [24]
upon addition of 1 Ag/well of the promoter-luciferase vector.
In addition, 50 ng/well of the lacZ-expressing vector
pCH110 (Pharmacia) were cotransfected to correct for
differences in transfection efficiency. After the appropriate
incubation times, cells were lysed in reporter lysis buffer
(Promega). Luciferase activity in the lysate was determined
using the luciferase assay kit (Promega), according to the
manufacturer’s protocol. h-Galactosidase activity was
assayed as described [25] using Galacton plus (Tropix) as
the substrate.
2.3. Electrophoretic mobility shift assays
Nuclear extracts from Tera-2 cells were prepared as
described by Schreiber et al. [26]. Extracts (10–15 Ag)
were incubated with 3 104 cpm 32P-labelled DNA, 2 Ag
dI–dC and, if necessary, unlabelled competitor DNA in a
reaction buffer (20 mM Hepes pH 7.9, 50 mM NaCl, 1 mM
EDTA, 0.15 mM EGTA, 1 mM DTT, 0.15 mM PMSF, 4%
(w/v) Ficoll and 50 mM KCl) for 5 min at room temper-
ature. The resulting protein–DNA complexes were separa-
ted on a 4% polyacrylamide gel using 0.5TBE as running
buffer [24] and visualized on X-ray film (Kodak X-Omat,
Fuji RX).
2.4. Synthetic oligonucleotides
The following synthetic oligonucleotides were obtained in
single-stranded form in both the sense and anti-sense direc-
tion: parATTA (5V-CTATAACATTGAATCAATTACAA-3V),
m-PBX (5V-CTATAACAGGGAAGCAATTACAA-3V), m-
P.H.L.J. Joosten et al. / Biochimica et Biophysica Acta 1588 (2002) 254–260 255
PRX (5V-CTATAACATTGAATCTAGAGCAA-3V), DM (5V-
CTATAACAGGGAAGCTAGAGCAA-3V), consensus CRE
(5V-AGAGATTGCCTGACGTCAGAGAGAAG-3V), con-
sensus AP1 (5V-CGGATGACTCAGCCGGAA-3V) and con-
sensus AP2 (5V-GATCGAACTGACCGCCCGCGGCCGT-
3V).
Equal amounts of the sense and anti-sense oligonucleo-
tides were mixed in distilled water, heated to boiling temper-
ature and slowly cooled to room temperature. If necessary,
the resulting double-stranded product was subsequently
purified by non-denaturating polyacrylamide gel electropho-
resis [24].
2.5. Antibodies
Anti-PBX polyclonal antibodies were directed against the
C-terminus of the human protein, recombinantly prepared as
a GST fusion protein (a generous gift from Dr. C. Murre,
UCSD). Polyclonal antibodies specific for PRX2 (aPrx2)
were directed against a synthetic peptide derived from mouse
Prx2 (IKSYGQEAAIEQPVAPRPTT), while polyclonal anti-
bodies recognizing both PRX1 and PRX2 (aPrx1 + 2) were
generated against the E. coli recombinant protein AGRRA-
AGPVSGPAEARVGAAREPSGGSSGTEAAPQDGDCPS-
PGRGTKRKKKQRRNRTTFNSSQLQALERVFERTHYP-
DAFVREELARRVNLSEARVQVWFQNRRAKFRRNER-
AMLATRSASLLKSYGQEAAIEQPVAPRPTTMSP-
DYLSWPASSPYSSVPPYSPGGSSPATPGVNMAN-
SIASLRLKAKEFSLHHSQVPTVN. Both antibodies were a
generous gift from Dr. F. Meijlink, Hubrecht Laboratory,
Utrecht.
3. Results
We have previously shown that the activity of the so-
called PDGFRA P1-promoter is strongly up-regulated upon
RA treatment of undifferentiated Tera-2 human embryonal
carcinoma cells. Up-regulation was also observed in the
presence of Bt2cAMP, such that synergy in promoter acti-
vation was observed by a combination of RA and this
cAMP analogue [21]. Since the promoter region tested does
not contain sequences corresponding to consensus RA- or
cAMP-responsive elements, a panel of progressive 5V-dele-
tion mutants of the promoter, cloned into a luciferase
reporter gene vector, was used to map the cis-element(s)
involved in the RA- and cAMP-induced promoter activity.
Upon transient transfection into undifferentiated Tera-EC
cells, the promoter activity of the deletion mutants varied in
agreement with previous data [21], but for each mutant, a 9-
to 20-fold induction of activity was observed upon treatment
of the cells for 48 h with RA alone or with RA in
combination with Bt2cAMP and the phosphodiesterase
inhibitor theophylline (RACT), as shown in Fig. 1. Interest-
ingly, similar results were obtained when the transfections
were performed in Tera-2 cells that had already been differ-
entiated by RA treatment for 7 days (Tera-RA cells). Since
these differentiated cells already display a high basal
PDGFRA promoter activity [21], RA and RACT seem to
enhance, rather than induce, promoter activity. The obser-
vation that the smallest element tested is still RA- and
Bt2cAMP-responsive, suggests that these stimuli mediate
their effects through regulating elements within the  52/
+ 118 region of the PDGFRA gene.
To characterize the transcription factors that bind to this
specific promoter region, electrophoretic mobility shift
assays (EMSAs) were performed using the  52/ + 118
promoter fragment as a probe. As shown in Fig. 2 (lane
1), at least four different complexes were observed upon
incubation of this fragment with nuclear extracts of Tera-EC
cells. Upon 24 h treatment of these cells with RA, quanti-
tative changes were observed in the three low mobility
complexes, while the high mobility complex had disap-
peared in favour of two new complexes with even higher
mobilities. Qualitatively similar differences, although often
more pronounced, were observed 24 h after treatment with
RACT (data not shown, see also Ref. [21]). These data show
that RA treatment of Tera-2 cells results in a complex but
Fig. 1. RA and cAMP-induced activity of PDGFRA promoter deletion mutants. Indicated 5Vpromoter-luciferase (LUC) deletion mutants were transiently
transfected into undifferentiated Tera-EC or differentiated Tera-RA cells. Transfected cells were treated for 48 h with either 5 AM RA or a combination of 5 AM
RA, 1 mM Bt2cAMP and 350 AM theophylline (RACT). Subsequently, luciferase activity in the cells was determined and corrected for differences in
transfection efficiency. The values represent the fold induction of luciferase activity after treatment relative to that of unstimulated cells, including the sample
standard deviation based on two independent experiments. Unstimulated values were in agreement with Afink et al. [21].
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characteristic change in nuclear protein binding to the  52/
+ 118 promoter fragment of PDGFRA.
The PDGFRA promoter does not contain a consensus RA-
responsive element, but it contains various putative binding
sites for RA-inducible transcription factors such as AP2 [21],
and one such AP2 site ( + 97GCCGTGGG+ 104) is located
within the  52/ + 118 region. In addition, an ATTA-con-
taining sequence ( + 4ATTGAATCAATTA+ 16), designated
here as parATTA, is present which shows some homology
to both a cAMP-responsive element (TGACGTCA) and to
binding sites for the AP1 transcription factor complex
(TGASTCA) [27,28]. In order to investigate the involvement
of these sequences in the  52/ + 118 promoter region in
binding of nuclear proteins, we carried out oligonucleotide
competition studies, as shown in Fig. 2. Competition with the
unlabelled parATTA oligonucleotide resulted in a complete
loss of five of the six previously mentioned protein–DNA
complexes bound to the  52/ + 118 probe. This shows that
this parATTA element is essential for the formation of
protein–DNA complexes in both Tera-EC and Tera-RA cells.
No binding competition was observed with a consensus APl
oligonucleotide, an AP2 oligonucleotide or an oligonucleo-
tide containing a cAMP-responsive element (CRE), which is
indicative for the specificity of nuclear protein binding to the
parATTA sequence in this promoter element (Fig. 2).
ATTA motifs are known to be involved in the DNA
binding of homeobox-containing transcription factors. A
search for transcription factor binding sites in the parATTA
sequence present in the  52/ + 118 fragment of the
PDGFRA promoter (TFSEARCH analysis) revealed the
highest correlation with binding sites for members of the
PBX and PRX families of homeobox proteins (TTGAAT
and AATTA, respectively). In order to identify if such
factors indeed bind the parATTA sequence in Tera-2 cells,
we used specific antibodies directed against PBX and PRX
proteins in EMSA studies. Fig. 3 shows that upon incuba-
tion of parATTA with nuclear extracts of Tera-EC cells, a
small increase in gel mobility of the DNA–protein complex
was observed in the presence of antibodies specific for
PBX2. More pronounced, a clear supershift was observed
when the experiment was carried out in the presence of
antibodies specific for PRX2, while antibodies that recog-
nize both PRX2 and its transcriptional partner PRX1
[22,29,30] strongly reduce DNA–protein complex forma-
tion. These data suggest that the parATTA sequence is
bound by PRX2, and possibly also PRX1, most likely in a
protein complex with PBX2. Similar results were obtained
using nuclear extracts from Tera-RA cells (data not shown).
In order to analyse the specific function of the bound
nuclear proteins, we introduced inactivating mutations into
the parATTA oligonucleotide on positions that are specific for
binding of either PBX2 or PRX1/2 (based on TFSEARCH
Fig. 2. EMSA on nuclear extracts of Tera-EC cells before (control) and 48 h
after incubation with 5 AM RA. Use was made of the 32P-labelled  52/
+ 118 PDGFRA promoter fragment, either in the absence of any specific
competitor (NO), or in the presence of a 500-fold excess of consensus AP1,
parATTA, consensus AP2 or consensus CRE oligonucleotide (see Materials
and methods for sequences). The five distinct DNA–protein complexes that
can be competed with unlabelled parATTA are indicated by arrows,
specified as complexes up-regulated by RA ( < ) and complexes with
decreased intensity following RA treatment (>).
Fig. 3. Identification of parATTA binding proteins in Tera-EC cells. EMSAs
were performed on the 32P-labelled PDGFRA promoter-derived parATTA
oligonucleotide, using nuclear extracts of Tera-EC cells in the presence of
anti-PRX and anti-PBX antibodies, as follows: ne, control nuclear extracts;
aPbx2, antibodies specific for PBX2; aPrx2, antibodies specific for PRX2;
aPb/rx2, a combination of aPbx2 and aPrx2; serum, control rabbit serum
in the absence of nuclear extract; aPrx1/2, antibodies recognizing both
PRX1 and PRX2. Arrows denote the DNA–protein complexes that are
formed or altered upon antibody binding.
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analysis). Fig. 4 shows that mutation of the putative PBX
binding site in the parATTA oligonucleotide results in a
strongly reduced ability to bind Tera-2 nuclear proteins.
Similar results were obtained upon mutation of the ATTA
site involved in PRX1/2 binding, while no detectable com-
plex formation was observed when both sites were mutated
simultaneously. The similarity in effect observed upon muta-
tion of the putative PBX and PRX site suggests that inhibition
of binding of one of these factors may already block for-
mation of the entire complex. It has been described that HOX
gene products may modulate the DNA binding activity of
PBX transcription factors and consequently that removal of
either PBX itself or of the homeobox-containing transcription
factor is sufficient for dissociation of the DNA–protein
complex [31]. In agreement with this observation, we find
that PBX2 only forms stable complexes with specific DNA
sequences when other homeobox-containing transcription
factors, in this case PRX1/2, are bound in addition.
Functional analysis of the wild-type and various mutated
parATTA elements was subsequently studied within the
context of the highly active  441/ + 118 promoter-lucifer-
ase reporter construct. When transfected into Tera-EC cells,
the various mutations in the parATTA element caused a
severe reduction in promoter activity compared to the wild-
type promoter, as shown in Fig. 5. Mutation of the putative
PBX binding site resulted in a more than 5-fold reduction in
luciferase activity, both before and after RACT treatment. A
similar reduction was observed upon mutation of the ATTA
site or when both sets of mutations were combined. A
complete loss of promoter activity was observed upon
deletion of 11 nucleotides from the palindromic sequence
within parATTA which is involved in binding of PBX and
PRX1/2. Since this deletion leaves the transcription initia-
tion intact, these data underline the essential role of the
parATTA element in the basal transcriptional activity of the
PDGFRA promoter.
4. Discussion
In the present study, we have shown that the up-regu-
lation of PDGFRA expression during differentiation of early
embryonic human cells requires a promoter element, des-
ignated parATTA, which binds a complex of PRX and PBX
proteins. Various studies have shown that improper expres-
sion of the PDGFRA during embryonic development can
result in NTDs, and therefore both PDGFRA itself and
genes encoding upstream regulators of its expression may
Fig. 5. Effect of mutations in the parATTA element on PDGFRA promoter
activity. In the  441/ + 118 PDGFRA promoter construct linked to
luciferase, the following mutations were made: P1, no mutation; D11, P1
carrying a deletion of the 11 nucleotide inverted repeat + 4ATTGAAT-
CAAT+ 14; m-Pbx, P1 carrying the PBX-sensitive mutation similarly as in
the m-PBX oligonucleotide; m-Prx, P1 carrying the PRX-sensitive mutation
similarly as in the m-PRX oligonucleotide; Dm, P1 carrying both sets of
mutations similarly as in the DM oligonucleotide. Constructs were
transfected into Tera-EC cells and luciferase (luc) activity was measured
in control cells ( ) and in cells treated for 48 h with RACT (+). Promoter
activity values were corrected for differences in transfection efficiency,
expressed in h-galactosidase (bgal) activity. Error bars represent the
standard deviation of duplicate independent experiments.
Fig. 4. Effect of mutations in the parATTA sequence on nuclear protein
binding. EMSAs were performed with nuclear extracts of Tera-EC cells
using 32P-labelled oligonucleotides with different mutations. The sequences
of the wild-type parATTA oligonucleotide and of the mutant forms aimed at
preventing PBX and PRX binding (designated m-PBX, m-PRX, and the
double mutant DM) are shown in Materials and methods. The arrow
denotes the major specific DNA–protein complex.
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be associated with such malformations. We have previously
shown that PAX1, as a product of a NTD-associated gene, is
an upstream regulator of PDGFRA expression, while the
current study identifies PBX2, PRX2 and possibly also
PRX1 as regulators of PDGFRA expression that are poten-
tially involved in NTDs. These observations are in line with
mouse studies, where severe NTDs have been observed,
particularly in Prx1( / ); Prx2( / ) mice, with similar
vertebrae defects as seen in the Pdgfra null mutant [22].
The exact nature of the protein complex that binds the
parATTA element in Tera-2 cells is unclear, but the obser-
vation that five distinct DNA–protein complexes have been
identified in this study that are competed in EMSAs by
unlabelled parATTA-containing oligonucleotides, indicates
that multiple complexes are formed. This suggests that in
addition to PBX2 and PRX1/2, other proteins may also be
present in the complexes formed. The EMSAs indicate that
PBX2- and PRX1/2-containing complexes can be formed
with nuclear extracts from both undifferentiated and differ-
entiated Tera-2 cells, indicating that the increase in
PDGFRA promoter activity upon RA treatment is most
likely not due to the induction of these homeotic genes.
These observations suggest that PBX–PRX proteins form
the core of a larger complex that is required for transcrip-
tional activation, in agreement with recent data on the
binding of such transcription factors to a collagen promoter
[32]. The formation of this complex is at most only partly
regulated by the mere availability of the transcription factors
involved and most likely requires an additional activation
step. This is confirmed by the observed synergy between
Bt2AMP and RA, which in comparison with RA alone gives
rise to only quantitative, and not to qualitative changes in
transcription factor binding to the  52/ + 118 region [21].
Also the observation that RACT still stimulates PDGFRA
transcription in Tera-RA cells supports this hypothesis.
The present data indicate that the parATTA binding
proteins PBX2 and PRX1/2 are essential for formation of
the complex that regulates PDGFRA expression during
embryonic cell differentiation. Homeobox transcription fac-
tors are known to control expression of other homeotic
genes, but only few examples are available in which they
control expression of non-homeotic genes such as PDGFRA
[32]. Amino acid alignment reveals that members of the
PBX and PRX families are 93–99% conserved between
mouse and human, while the parATTA element itself is
100% conserved between rat, mouse and human. This
underlines the importance of this mechanism for normal
vertebrate development.
Studies on the promoters of the human, mouse and rat
Pdgfra gene have provided evidence for the involvement of
GATA4 [33], PAX3-FKHR [7], Pax1 [5], C/EBPs [34] and
Gli1 [35] in transcriptional control. Potentially, the genes
encoding these transcription factors can all be involved in
the development of NTDs. In mice, Pdgfra itself as well as
Pax1, Pax3, Prx1 and Prx2, which all encode upstream
regulators of PDGFRA expression, have been associated
directly with NTDs. In humans, specific combinations of
PDGFRA promoter haplotypes have been associated with
predisposition to NTDs, while mutations in PAX1 and PAX3
are also considered to be risk factors for human NTDs.
Based on our present results, PBX2, PRX2 and possibly
PRX1 as well should also be considered as candidate genes
in the genesis of NTDs in humans. Further studies will have
to indicate if mutations in these genes or alterations in their
expression levels are indeed observed in patients suffering
from anencephaly and spina bifida.
In conclusion, we have shown that PDGFRA promoter
activity in human Tera-2 cells is strongly up-regulated upon
RA and cAMP treatment. The element involved is located in
the  52/ + 118 region of the promoter, and EMSAs show
that multiple protein complexes that can bind this region
which are all competed by a 23 bp parATTA oligonucleo-
tide. These protein complexes include PRX and PBX, but
since these complexes are present in both Tera-EC and Tera-
RA cells, RA/cAMP-induced induction of PDGFRA pro-
moter activity seems to require an additional, as yet
unknown activation step. Point mutations in parATTA
reduce binding affinity for PBX–PRX proteins and thereby
the induction of promoter activation by RA/cAMP. It is
therefore concluded that the parATTA sequence is essential
for normal PDGFRA transcription regulation and for its
activation upon RA/cAMP treatment.
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